bpc-157 safety toxicity review The Hidden Risks of BPC‑157: What Patients Need to Know About Contamination and The hype around a new

Build trust with clients through expert knowledge and safe practices

BPC-157 provides a powerful antidote to this pathology

Early evidence for the potential efficacy of this route was published in 1999, where 18 patients with B12 deficiency treated exclusively with 712 days of 2 mg of sublingual cobalamin daily had 4 times higher B12 levels compared to pre-treatment, reaching therapeutic ranges ( There have also been further studies comparing treatment outcomes from the sublingual route to the more established IM and oral routes

Zhang W, Jing Y, Wang S, Wu Y, Sun Y, Zhuang J, Huang X, Chen S, Zhang X, Song Y (2022a) Identification of biological functions and prognostic value of NNMT in oral squamous cell carcinoma